Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00982020 · ClinicalTrials.gov registry record · Phase 4
Study in Adolescents With Schizophrenia or Bipolar Disorder
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 203
- Enrollment target
NCT00982020 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 203 participants.
The verdict
NCT00982020, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 203 participants
- Enrollment target
Study Summary
Open-label safety study of oral olanzapine treatment in adolescents, aged 13 to 17 years, with bipolar I disorder (manic or mixed episodes) or schizophrenia.
Interventions
- DRUG Olanzapine
- BEHAVIORAL Standard behavioral weight intervention
- BEHAVIORAL Intense behavioral weight intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00982020
The ClinicalTrials.gov registry entry for NCT00982020 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Olanzapine is the first listed.
NCT00982020 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00982020 about?
NCT00982020 is a clinical study titled "Study in Adolescents With Schizophrenia or Bipolar Disorder". Open-label safety study of oral olanzapine treatment in adolescents, aged 13 to 17 years, with bipolar I disorder (manic or mixed episodes) or schizophrenia.
What is the current status of trial NCT00982020?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 203 participants. The study started on 2009-09. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00982020?
The interventions under investigation include: Olanzapine (DRUG), Standard behavioral weight intervention (BEHAVIORAL), Intense behavioral weight intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT00982020?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.